摘要
颅内动脉瘤(IA)是颅内动脉壁的某一部分因病变而向外突出所形成的永久性扩张,是造成蛛网膜下腔出血的首位病因。定量蛋白质组学,作为新近出现的一种崭新的研究手段,为治疗颅内动脉瘤提供了新的研究思路。通过同位素标记相对和绝对定量(iTRAQ)技术及二维液相色谱-串联质谱(2D-LC-MS/MS)法筛选动脉瘤壁差异表达蛋白质,为动脉瘤形成和破裂的分子机制研究提供了帮助。本文综述了颅内动脉瘤的研究进展以及定量蛋白质组学技术在颅内动脉瘤研究中的应用。
The intracranial aneurysm （IA） is a cerebrovascular disorder in which the weakness in the wall of a cerebral artery or vein causes a localized dilation or ballooning of the blood vessel. The quantitative proteomics is to obtain quantitative information about all proteins in a sample. The quantitative proteomics is mainly performed by isobaric tagging for relative and absolute quantitation （iTRAQ） and 2-DE or mass spectrometry （MS）. The identification of the proteins related to the intracranial aneurysm （IA） wall biological activities could help to find novel pathological mechanisms and therapeutic targets for the human intracranial aneurysm. This paper reviews the applications of quantitative proteomics technology in the study of intracranial aneurysm.
出处
《科技导报》
CAS
CSCD
北大核心
2017年第4期60-63,共4页
Science & Technology Review
基金
国家科技支撑计划项目(2015BAI12B04)
北京市医院管理局"使命"计划项目(SML20150501)
关键词
脑血管疾病
颅内动脉瘤
定量蛋白质组学
同位素标记相对和绝对定量技术
cerebrovascular disease
intracranial aneurysms
quantitative proteomics technology
isobaric tagging for relative and absolute quantitation
